Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
On November 4, Nobel laureate Joseph Stiglitz handed President Cyril Ramaphosa the world’s first G20 Inequality Report, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback